Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of supervised exercise during neoadjuvant nab-paclitaxel + carboplatin in triple negative breast cancer
2016-002435-15Phase 4Active
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Jun 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nab-paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fundación de Investigación HM Hospitales. Primary endpoints: Study results and publications and Changes in metabolomic profile. Started Jun 2017; status: active.
02
Drugs
nab-paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-002435-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002435-15.